Krystal Biotech Inc. (KRYS)

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

I maintain a Strong Buy on Krystal Biotech, as the pause in melanoma trial enrollment is offset by promising progress in inhaled KB707 for NSCLC. Inhaled KB707 achieved a 36% ORR in heavily pretreated...

Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.

Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Kathryn A. Romano - Executive VP & Chief Accounting Officer Krish S.

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $0.86 per share a year ago.

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.